{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '10.4.2 Serious adverse events waived from expedited regulatory reporting to regulatory', 'authorities', 'Not applicable.', '10.4.3 General guidelines for reporting adverse events', 'All AEs, regardless of seriousness or relationship to IMP/NIMP, spanning from the', 'signature of the ICF form until the end of the study as defined by the protocol for that', 'patient, are to be recorded on the corresponding page(s) or screen(s) of the e-CRF.', 'Whenever possible, diagnosis or single syndrome should be reported instead of symptoms.', 'The Investigator should specify the date of onset, intensity, action taken with respect to', 'IMP, corrective treatment/therapy given, additional investigations performed, outcome,', 'and his/her opinion as to whether there is a reasonable possibility that the AE was caused', 'by the IMP or by the study procedure(s).', 'The Investigator should take appropriate measures to follow all AEs until clinical recovery', 'is complete and laboratory results have returned to normal, or until progression has been', 'stabilized, or until death, in order to ensure the safety of the patients. This may imply that', 'observations will continue beyond the last planned visit per protocol, and that additional', 'investigations may be requested by the monitoring team up to as noticed by the Sponsor in', 'the protocol and informed consent. At the prespecified study end date, patients who', 'experience an ongoing SAE or an AESI should be followed until resolution, stabilization,', 'or death and related data will be collected.', \"When treatment is prematurely discontinued, the patient's observations will continue until\", 'the end of the study as defined by the protocol for that patient.', 'Laboratory, vital signs are to be recorded as AEs only if:', '-', 'Symptomatic and/or,', '-', 'Requiring either corrective treatment or consultation, and/or,', '-', 'Leading to IMP discontinuation or modification of dosing, and/or,', '-', 'Fulfilling a seriousness criterion, and/or,', '-', 'Defined as an AESI.', 'In this protocol, symptoms and signs of exacerbation or worsening of the disease under trial will', 'usually be captured in the context of efficacy assessment, and recorded on the relapse module of', 'the e-CRF. Therefore, symptoms, relapses or worsening of MS will not be considered as AEs nor', 'captured on the AE module of the e-CRF unless this event is considered possibly or probably', 'related to the IMP (ie, worsening is not consistent with the anticipated natural progression of the', 'disease) and/or the MS relapse meets the criteria for a serious AE (eg, requires hospitalization).', 'However, for all associated symptoms or events or if an event that was initially considered a', 'possible MS relapse but upon evaluation is found to be any other type of event (some example but', 'not limited to: fever, injury, musculoskeletal event, systemic illness, mood disorder, etc) the event', 'must be captured as an AE/SAE.', 'Instructions for AE reporting are summarized in Table 9.', 'Property of the Sanofi Group - strictly confidential', 'Page 80', 'VV-CLIN-0254406 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', '10.4.4 Instructions for reporting serious adverse events', 'In the case of occurrence of an SAE or AESI, the Investigator or any designees must immediately:', 'ENTER (within 24 hours) the information related to the SAE or AESI in the appropriate', 'screens of the e-CRF; the system will automatically send a notification to the monitoring', 'team after approval of the Investigator within the e-CRF or after a standard delay.', 'There may be instances when copies of medical records for certain cases are requested by', \"the Sponsor. In such case, care should be taken to ensure that the patient's identity is\", \"protected and the patient's identifiers in the study are properly mentioned on any copy of a\", 'source document provided to the Company. For laboratory results, include the laboratory', 'normal ranges', 'All further data updates should be recorded in the e-CRF as appropriate, and further', 'documentation as well as additional information (for laboratory data, concomitant', 'medications, patient status, etc) should be sent (by fax or e-mail) to the monitoring team', 'within 24 hours of knowledge of the SAE or AESI. In addition, every effort should be', 'made to further document any SAE that is fatal or life-threatening within a week (7 days)', 'of the initial notification.', 'A back-up plan (using a paper CRF process) is available and should be used when the', 'e-CRF system does not work.', 'Any SAE brought to the attention of the Investigator at any time after the end of the study for the', 'patient and considered by him/her to be caused by the IMP with a reasonable possibility, should', 'be reported to the monitoring team.', '10.4.5 Guidelines for reporting adverse events of special interest', 'For AESIs, the Sponsor must be informed immediately (ie, within 24 hours), as per SAE', 'notification guidelines described in Section 10.4.4 even if not fulfilling a seriousness criterion,', 'using the screens in the e-CRF.', 'Instructions for AE reporting are summarized in Table 9.', '10.4.6 Guidelines for management of specific laboratory abnormalities', 'Decision trees for the management of certain laboratory abnormalities by sanofi are provided in', 'Appendix B.', 'The following laboratory abnormalities should be monitored, documented, and managed', 'according to the related flow chart in protocol appendices.', 'Neutropenia.', 'Thrombocytopenia.', 'ALT increase.', 'Acute renal insufficiency.', 'Suspicion of rhabdomyolysis.', 'Property of the Sanofi Group - strictly confidential', 'Page 81', 'VV-CLIN-0254406: 5.0']\n\n###\n\n", "completion": "END"}